C/EBP-β-mediated upregulation of CaV1.2 calcium channel increases arterial constriction in mice with ibrutinib-associated hypertension
Journal of Clinical Investigation · 12.11.2026
DOI: 10.1172/jci203386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 12.11.2026. Verfasst von Ludan Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine,…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Ibrutinib, a Bruton's tyrosine kinase inhibitor, is indicated for treating chronic lymphocytic leukemia (CLL), but hypertension is a common cardiovascular adverse event. Previous studies have linked ibrutinib to cardiac events through dysregulated intracellular calcium handling, but the mechanisms underlying ibrutinib-associated hypertension remain largely unknown. Here, we followed up 225 CLL patients receiving ibrutinib or managed with watch-and-wait strategy, and identified ibrutinib as an independent risk factor for hypertension. In mice, ibrutinib elevated arterial blood pressure (BP) without structural remodeling of small arteries, and it potentiated K + -induced vasoconstriction. In vascular smooth muscle cells (VSMCs), ibrutinib upregulated Ca V 1.2 channel expression and function, as evidenced by enhanced Ca V 1.2 currents and K + -triggered-[Ca 2+ ] i elevation. Mechanistically, ibrutinib suppressed casein kinase 2 (CK2)-mediated HSP90β phosphorylation, and stabilized C/EBP-β, which bound to the promoter of Cacna1c gene and drove CaV1.2 transcription. Significantly, C/EBP-β knockdown attenuated ibrutinib-induced Ca V 1.2 hyperactivity and vasoconstriction. Collectively, these findings reveal a CK2-HSP90β-C/EBP-β-Ca V 1.2 signaling cascade through which ibrutinib enhances vascular Ca 2+ influx and vasoconstriction, thereby elevating arterial BP. Thus, this study nominates C/EBP-β as a therapeutic target for ibrutinib-associated hypertension.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, China.
- The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
- Department of Rehabilitation, Jiangsu Province People's Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, L., Yin, S., Hou, W., Yang, D., Jia, Y., Liu, Y., Wang, Y., Zhao, S., Gao, X., Sun, X., Lu, X., Li, J., Chu, M., Xiong, X., Zhu, H., & Wang, J. (2026). C/EBP-β-mediated upregulation of CaV1.2 calcium channel increases arterial constriction in mice with ibrutinib-associated hypertension. Journal of Clinical Investigation. https://doi.org/10.1172/jci203386
Vancouver
Zhang L, Yin S, Hou W, Yang D, Jia Y, Liu Y, et al. C/EBP-β-mediated upregulation of CaV1.2 calcium channel increases arterial constriction in mice with ibrutinib-associated hypertension. Journal of Clinical Investigation. 2026. doi:10.1172/jci203386
BibTeX
@article{Zhang2026,
author = {Zhang, Ludan and Yin, Shumin and Hou, Wei and Yang, Dan and Jia, Yiyuan and Liu, Yun and Wang, Yan and Zhao, Sirui and Gao, Xiaoyan and Sun, Xiaolin and Lu, Xiao and Li, Jianyong and Chu, Ming and Xiong, Xiaoqing and Zhu, Huayuan and Wang, Juejin},
title = {C/EBP-β-mediated upregulation of CaV1.2 calcium channel increases arterial constriction in mice with ibrutinib-associated hypertension},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci203386}
}
EUVIMED